https://ijper.in/index.php/IJPER/issue/feedINTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER)2026-07-17T12:59:19+00:00Ms. Payal Kesharwaniijper.editor@gmail.comOpen Journal Systems<p><strong>International Journal of Pharmaceutical Education and Research</strong> (IJPER) is an international, peer-reviewed, open access journal devoted to various segments of pharmaceutical sciences. It’s a biannually published journal that publishes quality manuscripts (original research, reviews, short communications, mini-reviews and case reports) relevant to the various fields of Pharmaceutical Sciences. </p> <table border="1" cellspacing="0" cellpadding="5"> <tbody> <tr> <td valign="top" width="265"> <div align="center"><strong> </strong><strong>Starting Year</strong><br>2019</div> </td> <td valign="top" width="301"> <div align="center"><strong>Journal ISSN<br></strong>2582-2152 (Online)</div> </td> <td valign="top" width="234"> <div align="center"><strong>CrossRef DOI Prefix</strong><br>10.37021</div> </td> <td valign="top" width="218"> <div align="center"><strong>Frequency</strong><br>2 Issues/Year (Biannual)</div> </td> </tr> <tr> <td valign="top"> <div align="center"><strong> </strong><strong>Publishing System</strong></div> <div align="center">Open Journal System<strong><br> </strong> (OJS) by Public knowledge Project (PKP)</div> </td> <td valign="top"> <div align="center"><strong>Copyright License Type</strong></div> <div align="center">Creative Common Attribution-NonCommercial 4.0 International<br>(CC BY-NC-SA 4.0)</div> </td> <td valign="top"> <div align="center"><strong>Email</strong></div> <div class="style1" align="center">ijper.editor@gmail.com</div> <div class="style1" align="center">editor@ijper.in</div> </td> <td valign="top"> <div align="center"><strong>Primary Contact</strong></div> <div align="center">+91-7974318397</div> </td> </tr> </tbody> </table> <p> </p> <p><strong>Journal Abbreviation:</strong> <em>Int. J. Pharm. Edu. Res.</em></p> <p><strong>Indexing:</strong> International Journal of Pharmaceutical Education and Research, IJPER is indexed with <a href="https://scholar.google.co.in/citations?user=CEhnT44AAAAJ&hl=en">Google Scholar</a>, <a href="https://www.researchgate.net/journal/2582-2152_INTERNATIONAL_JOURNAL_OF_PHARMACEUTICAL_EDUCATION_AND_RESEARCH_IJPER">ResearchGate,</a> World Cat, <a href="https://cassi.cas.org/publication.jsp?P=DXaT8ZV7yNcyz133K_ll3zLPXfcr-WXfNKTEt1-l894yz133K_ll3zLPXfcr-WXf-9sRQmIIxJMyz133K_ll3zLPXfcr-WXfIY0JLEXX41RsDpuJibhy6A">CAS Source Index (CASSI)</a>, <a href="https://portal.issn.org/resource/ISSN/2582-2152#">ROAD (Directory of Open Access Scholarly Resources)</a>, <a href="http://journalseeker.researchbib.com/?action=viewJournalseekerSearch">Research Bible (Academic Resource Index)</a>, <a href="https://www.sciencegate.app/source/401708839">SCIENCEGATE</a>, <a href="http://olddrji.lbp.world/JournalProfile.aspx?jid=2582-2152">Directory of Research Journals Indexing (DRJI)</a>, Index Copernicus (ICV), Crossref, and many more.</p> <p><strong>Why IJPER?</strong></p> <ul> <li class="show">Global audience with Open and immediate access to all publications.</li> <li class="show">Worldwide dissemination through OJS platform.</li> <li class="show">Prompt and unbiased review process.</li> <li class="show">Indexed with the most important international bibliographic databases.</li> <li class="show">Regular alerts on E-mail</li> </ul> <p><strong>Articles invited for Volume 6, Issue 2.</strong></p>https://ijper.in/index.php/IJPER/article/view/383The Evolving Landscape of Nano-Emulsion Drug Systems in diabetes: Updated Review2026-07-17T11:38:19+00:00Aslam .rohitkumar705441@gmail.comArabind Kumarrohitkumar705441@gmail.comAnuj .rohitkumar705441@gmail.comRohit .rohitkumar705441@gmail.comVivek kushwaharohitkumar705441@gmail.comDeepak Kumarrohitkumar705441@gmail.comAbhimanyu Kumarrohitkumar705441@gmail.comTriloki Prasadrohitkumar705441@gmail.comThe use of Nano emulsion in augmenting dermal and transdermal effectiveness of drugs has now well established. The development of Nano emulsion based semisolid dosage forms is an active area of present research. The thickening or liquid-to-semisolid conversion of the nano-emulsions provides opportunities to the formulation scientist to explore novel means of solving instability issues during transformation. Conventional dosage forms of the anti-diabetic drugs exhibit variable/less bioavailability and short half-life, demanding frequent dosing and causing increased side-effects resulting in ineffectiveness of therapy and non-compliance with the patients. Considering the chronic nature of diabetes, nanotechnology-based approaches are more promising in terms of providing site-specific delivery of drugs with higher bioavailability and reduced regimen. Many studies have hinted at the possibility of administering peptide drugs like glucagon like peptides orally by encapsulation into nanoparticles. Nanoparticles also allow further modifications including their encapsulation into micro-particles, polyethylene glycol (PEG)-PEGylation- or functionalization with ligands for active targeting.2026-06-30T00:00:00+00:00##submission.copyrightStatement##https://ijper.in/index.php/IJPER/article/view/362Design and Computational Evaluation (Docking) of quinazoline–piperazine carboxamide derivatives as Potential Tyrosine Kinase Inhibitors.2026-07-17T12:57:05+00:00Shikha Sharmashikhasharma67230@gmail.comAbhishek Kashyapabhicall1210@gmail.comPallavi Mansih Lavhaleprincipalrit@rameesh.orgPushkar kumar Raypushkarkumarray34@gmail.comThe abnormal regulation of c-ABL tyrosine kinase linked with the BCR-ABL fusion gene remains the primary therapeutic focus in the management of Chronic Myeloid Leukemia (CML). While inhibitors such as Imatinib have shown notable clinical efficacy, the development of resistance mutations creates the need for new therapeutic candidates. In this regard, the present study reports the rational design and computational screening of a novel set of compounds, namely quinazoline–piperazine carboxamide derivatives, as prospective ATP-competitive inhibitors. These hybrid molecules were designed by merging the kinase inhibitory characteristics of the quinazoline core with the structural properties of the piperazine-carboxamide moiety. Molecular docking studies against the c-ABL kinase domain (PDB ID: 1IEP) identified high-affinity lead compounds with strong structural compatibility in the ATP-binding pocket. Interaction analysis demonstrated stable hydrogen bond formation in the hinge region along with notable stabilization of the DFG motif, indicating the anticancer potential of these derivatives. These outcomes offer a strong theoretical basis for further chemical synthesis and biological evaluation.2026-07-17T12:57:05+00:00##submission.copyrightStatement##https://ijper.in/index.php/IJPER/article/view/371Novel Phenolic Hydrazide–Hydrazones as Multi-Target Anti-Alzheimer Agents: Docking and ADMET Studies2026-07-17T12:59:19+00:00Ankit Agnihotriankitagnihotry777@gmail.comReema Sinhaankitagnihotry777@gmail.comAbhishek Kashyapankitagnihotry777@gmail.comAlzheimer's disease (AD) is a neurodegenerative ailment characterised by increasing cognitive impairment, memory loss and decreased cholinergic neurotransmission. Acetylcholinesterase (AChE) inhibitors are still one of the most efficient therapeutic strategies for symptomatic treatment of AD; nevertheless, the existing medications have significant drawbacks such as unpleasant effects and limited efficiency. Herein, creation and evaluation of a series of new phenolic hydrazide-hydrazone derivatives as possible AChE inhibitors on the basis of molecular docking and ADMET investigations are reported. Ten ligands (A01–A10) were rationally developed from previously described hydrazide–hydrazone pharmacophores with antioxidant and neuroprotective effects. Molecular docking investigations were conducted against crystal structure of AChE protein (PDB ID: 7E3H) using PyRx and AutoDock Vina software . The proposed compounds exhibited good binding affinity towards the active site of AChE with docking scores ranging from −10.4 to −11.8 kcal/mol. Among the synthesised analogues, A04, A06 and A10 showed superior docking scores and favourable interactions with important amino acid residues such as TYR337, TYR341 and GLY122 equivalent to the standard medicine donepezil (-11.9 kcal/mol). ADMET analysis using SwissADME showed adequate drug similarity, favourable pharmacokinetic features and conformity to Lipinski’s criterion for majority of the substances. The phenolic moiety may also have antioxidant and neuroprotective benefits. In conclusion, the present investigation reveals that phenolic hydrazide-hydrazone derivatives have potential anti-Alzheimer properties and they might be used as lead compounds for further synthesis, biological assessment and creation of safer and more efficient AChE inhibitors.2026-07-17T12:59:19+00:00##submission.copyrightStatement##https://ijper.in/index.php/IJPER/article/view/357Therapeutic Approaches to Enhance Neuronal Survival in Ischemic Stroke: Insights from Experimental Models2026-07-17T11:41:36+00:00Supriya Raniqumre.alam0109@gmail.comQumre Alamqumre.alam0109@gmail.comIschemic stroke remains a leading cause of morbidity and mortality worldwide, characterized by sudden interruption of cerebral blood flow leading to neuronal death through mechanisms such as excitotoxicity, oxidative stress, inflammation, and apoptosis. Experimental models, including rodent middle cerebral artery occlusion (MCAO) and in vitro oxygen-glucose deprivation (OGD), have been instrumental in elucidating these pathways and testing therapeutic interventions. This review synthesizes insights from preclinical studies on neuroprotective strategies, including pharmacological agents targeting excitotoxicity and oxidative stress, anti-inflammatory therapies, anti-apoptotic approaches, cell-based therapies, hypothermia, ischemic conditioning, and novel modalities like miRNA modulation and phytochemicals. Despite translational challenges, these models highlight promising avenues for enhancing neuronal survival, emphasizing the need for pleiotropic therapies and rigorous preclinical design to improve clinical outcomes.2026-07-17T11:41:36+00:00##submission.copyrightStatement##